Genzyme hopes to purchase rest of IG Laboratories:
This article was originally published in Clinica
Genzyme wishes to purchase the remaining shares of IG Laboratories, the genetic testing company in which it already has a 69% stake. It has approached IG's directors and proposed a tax-free merger under which IG stockholders would receive 0.12368 Genzyme shares for each IG share. This values IG shares at $4.76 - a premium of 29% on the share price prior to the offer - and the total transaction at $14 million.